Title | Investigative pathology: leading the post-genomic revolution. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, Fletcher CDM, Loda M |
Journal | Lab Invest |
Volume | 92 |
Issue | 1 |
Pagination | 4-8 |
Date Published | 2012 Jan |
ISSN | 1530-0307 |
Keywords | Academies and Institutes, Career Choice, Computational Biology, Genomics, Humans, Industry, Pathology, Molecular, Precision Medicine |
Abstract | The completion of the Human Genome Project and the development of genome-based technologies over the past decade have set the stage for a new era of personalized medicine. By all rights, molecularly trained investigative pathologists should be leading this revolution. Singularly well suited for this work, molecular pathologists have the rare ability to wed genomic tools with unique diagnostic skills and tissue-based pathology techniques for integrated diagnosis of human disease. However, the number of pathologists with expertise in genome-based research has remained relatively low due to outdated training methods and a reluctance among some traditional pathologists to embrace new technologies. Moreover, because budding pathologists may not appreciate the vast selection of jobs available to them, they often end up choosing jobs that focus almost entirely on routine diagnosis rather than new frontiers in molecular pathology. This review calls for changes aimed at rectifying these troubling trends to ensure that pathology continues to guide patient care in a post-genomic era. |
DOI | 10.1038/labinvest.2011.147 |
Alternate Journal | Lab Invest |
PubMed ID | 21986811 |
Grant List | R01CA131945 / CA / NCI NIH HHS / United States R01DK072000 / DK / NIDDK NIH HHS / United States |
Related Faculty:
Massimo Loda, M.D.